Fulcrum Therapeutics filed the paperwork for there IPO to raise up to $86 million on 6/21/19. The company has three small molecule candidates in development that aim to treat the root cause of a... read more
Karuna Therapeutics updated its IPO filing to include a new maximum of $85 million+. The company will offer 4,375,000 shares. The company plans to trade on NASDAQ... read more
Change Healthcare, which provides healthcare revenue cycle management software and services, announced terms for its IPO and equity offering on 6/14/19. The company will raise up to $900 million+... read more
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring... read more
Dermavant updated its filing on 6/10/19 and will issue 7,700,000 shares and raise up to $123.9 million. Roivant is the controlling shareholder and will have the right to appoint two directors to... read more
Precision immuno-oncology medicine company, Personalis, updated their IPO filing on 6/7/19. The company plans to offer 6,666,667 shares and raise up to $122+ million. Personalis plans to trade on... read more
As investor interest in early stage life science companies continues to grow, Third Rock has announced the closing of an oversubscribed fund focused on discovering, launching and building... read more
Clinical-stage biotech, Inhibrx filed the paperwork for its IPO. The company will raise up to $74,750,000 and intends to trade on NASDAQ under the symbol, “INBX.” Inhibrx is based in La Jolla, CA... read more
Seattle based, Adaptive Biotechnologies, has filed for a $230 Million IPO. The company currently offers tools for monitoring several cancer types, sequencing immune system components, and aiding... read more
EnteroBiotix, a leading clinical stage microbiome therapeutics company headquartered in Aberdeen, Scotland, has closed an oversubscribed seed extension investment and is set for international... read more
Fort Worth, TX May 28, 2019 — SOURCE EXPLORER, a life sciences supplier search and matching service, announced today that it has... read more
Microbiome Report for Week Ending 5/18/19
4D Pharma's Chron's Disease Treatment Meets Safety Objective
4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on... read more
Stoke Therapeutics filed for its IPO that could be worth up to $86 million. The Bedford, MA-based company is developing therapies to treat severe genetic diseases by, “precisely protein... read more
Fountain Healthcare Partners (“Fountain”) announced on 5/23/19 the initial closing of its third fund, Fountain Healthcare Partners Fund III, L.P. (“Fund III”) with €118 million of committed... read more
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced on 5/22/19 the pricing of its underwritten public offering of 7,000,000 shares of its... read more
Sofinnova Partners, a European venture capital firm specializing in Life Sciences, announced today the launch of MD Start III, which closed above its original target of €40 million. With this new... read more
